NCT07092709View on ClinicalTrials.gov

Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

912

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

December 31, 2028

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization, and within 24 hours of stroke onset.

DRUG

Placebo

Matched placebo is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization, and within 24 hours of stroke onset.

Trial Locations (1)

510000

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER